SANTA CRUZ BIOTECHNOLOGY, INC.

C2 (h): 293T Lysate: sc-114242



BACKGROUND

The complement component proteins, C2, C3, C4 and C5, are potent anaphylatoxins that are released during complement activation. Binding of these proteins to their respective G protein-coupled receptors induces proinflammatory events such as cellular degranulation, smooth muscle contraction, arachidonic acid metabolism, cytokine release, leukocyte activation and cellular chemotaxis. C2 deficiency (C2D) is the most common deficiency of the classical complement pathway and is mostly found in patients with autoimmune disease or susceptibility to bacterial infections. The N-terminal extracellular domain 1 of complement C2 receptor inhibitory trispanning, or CRIT, binds to C2 and specifically interacts with the C2 α fragment. In doing so, CRIT blocks C2 cleavage and also prevents the classical pathway of C3 convertase formation.

REFERENCES

- Manderson, A.P., Pickering, M.C., Botto, M., Walport, M.J. and Parish, C.R. 2001. Continual low-level activation of the classical complement pathway. J. Exp. Med. 194: 747-756.
- 2. Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 217000. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/
- Inal, J.M., Hui, K.M., Miot, S., Lange, S., Ramirez, M.I., Schneider, B., Krueger, G. and Schifferli, J.A. 2004. Complement C2 receptor inhibitor trispanning: a novel human complement inhibitory receptor. J. Immunol. 174: 356-366.
- 4. Skelly, P.J. 2004. Intravascular schistosomes and complement. Trends Parasitol. 20: 370-374.
- 5. Kitano, E. and Kitamura, H. 2005. Immunologic tests: C2. Nippon Rinsho 63: 59-62.
- Gold, B., Merriam, J.E., Zernant, J., Hancox, L.S., Taiber, A.J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., Barile, G.R., Smith, R.T., Hageman, G.S., Dean, M. and Allikmets, R. 2006. Variation in Factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 38: 458-462.
- Jönsson, G., Oxelius, V.A., Truedsson, L., Braconier, J.H., Sturfelt, G. and Sjöholm, A.G. 2006. Homozygosity for the IgG₂ subclass allotype G2M(n) protects against severe infection in hereditary C2 deficiency. J. Immunol. 177: 722-728.

CHROMOSOMAL LOCATION

Genetic locus: C2 (human) mapping to 6p21.33.

PRODUCT

C2 (h): 293T Lysate represents a lysate of human C2 transfected 293T cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

APPLICATIONS

C2 (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive C2 antibodies. Recommended use: 10-20 μl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.